Regeneron Pharmaceuticals Inc. has filed a lawsuit to prevent the South Korean company Celltrion Inc., from producing and marketing a biosimilar version of Eylea.
Lodged in the United States District Court for the Northern District of West Virginia, the complaint alleges that the biosimilar known as CT-P42 infringes 38 patents owned by Regeneron for Eylea, which is used to treat wet age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, diabetic retinopathy, and retinopathy of prematurity.
Phase III trials for CT-P42, announced on 3 April, 2023, demonstrated equivalence and similarity of CT-P42 to Eylea.
In November 2022, Celltrion won a trial against Regeneron in a United States patent lawsuit related to Eylea.
